Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21 WAF-induced differentiation triggered by GSK3beta inactivation and reduced AKT activity.
To investigate gene synergism in multistage skin carcinogenesis, the RU486-inducible cre/lox system was employed to ablate Pten function (K14.cre/Delta5Pten flx) in mouse epidermis expressing activated Fos (HK1.Fos). RU486-treated HK1.Fos/Delta5Pten flx mice exhibited hyperplasia, hyperkeratosis and tumours that progressed to highly differentiated keratoacanthomas, rather than to carcinomas, owing to re-expression of high p53 and p21 WAF levels. Despite elevated MAP kinase activity, cyclin D1 and cyclin E2 overexpression, and increased AKT activity that produced areas of highly proliferative papillomatous keratinocytes, increasing levels of GSK3beta inactivation induced a novel p53/p21 WAF expression profile, which subsequently halted proliferation and accelerated differentiation to give the hallmark keratosis of keratoacanthomas. A pivotal facet to this GSK3beta-triggered mechanism centred on increasing p53 expression in basal layer keratinocytes. This increase in expression reduced activated AKT expression and released inhibition of p21 WAF, which accelerated keratinocyte differentiation, as indicated by unique basal layer expression of differentiation-specific keratin K1 alongside premature filaggrin and loricrin expression. Thus, Fos synergism with Pten loss elicited a benign tumour context where GSK3beta-induced p53/p21 WAF expression continually switched AKT-associated proliferation into differentiation, preventing further progression. This putative compensatory mechanism required the critical availability of normal p53 and/or p21 WAF, otherwise deregulated Fos, Akt and Gsk3beta associate with malignant progression.
Yao
Denggao
D
Section of Dermatology, Division of Cancer Sciences, Glasgow University Faculty of Medicine, Robertson Building, Glasgow, G11 6NU, UK.
Alexander
Claire L
CL
Quinn
Jean A
JA
Chan
Weng-Chyn
WC
Wu
Hong
H
Greenhalgh
David A
DA
D000818:Animals; D056741:Cyclin D; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism*; D016213:Cyclins / Q000378:metabolism; D018450:Disease Progression; D015603:Keratinocytes / Q000166:cytology / Q000378:metabolism*; D007636:Keratoacanthoma / Q000378:metabolism*; D051379:Mice; D015735:Mifepristone / Q000494:pharmacology; D051058:Oncogene Protein v-akt / Q000378:metabolism; D016761:Oncogene Proteins v-fos / Q000378:metabolism*; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D012097:Repressor Proteins / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
C503689:Ccne2 protein, mouse; C493957:Cdkn1a protein, mouse; D056741:Cyclin D; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016761:Oncogene Proteins v-fos; D012097:Repressor Proteins; D016159:Tumor Suppressor Protein p53; D015735:Mifepristone; D051058:Oncogene Protein v-akt; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse